LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Combined Tests Provide Better Asthma Diagnosis

By LabMedica International staff writers
Posted on 10 Oct 2013
Print article
Image: Three eosinophils in a peripheral blood smear from a patient with eosinophilia (Photo courtesy of Ed Uthman, MD).
Image: Three eosinophils in a peripheral blood smear from a patient with eosinophilia (Photo courtesy of Ed Uthman, MD).
Fraction of exhaled nitric oxide (FENO) and blood eosinophil-count values, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients.

Measurement of the concentration of exhaled nitric oxide is today a routine clinical method for determining the degree of steroid-sensitive inflammation in the airways in asthma and for many years, a count of eosinophil granulocytes in the blood has also been used to support a diagnosis of asthma.

Scientists at Uppsala University (Sweden) measured FENO and eosinophil values in 12,408 subjects aged 6 to 80 years from 2007 to 2008 and from 2009 to 2010. Current wheeze and asthma diagnosis, as well as asthma attacks and asthma-related emergency department (ED) visits within the last 12 months, were assessed by means of questionnaires.

The FENO values were measured with the NIOX MINO electrochemical analyzer (Aerocrine AB; Solna, Sweden) at an expiratory flow rate of 50 mL/second. Blood differential counts were performed by using the automated HmX hematology analyzer (Beckman Coulter; Fullerton, CA, USA). The following cutoffs for eosinophil values were used: less than 300 cells/mm3 to define normal values; 300 cells/mm3 or greater but less than 500 cells/mm3 for intermediate values and 500 cells/mm3 or greater for high values, as this is the limit for defining eosinophilia.

The scientists were able to determine that the association between FENO and blood eosinophils was very weak. Instead, they observed that simultaneously elevated levels of the two markers, in a synergistic way, but independently of each other, increased the likelihood of individuals reporting, for example, asthma symptoms or asthma attacks in the last year. The results supported their hypothesis that the two markers represent two different inflammation processes.

Kjell Alving, PhD, a professor at the Department of Children's and Women's Health, Uppsala University, and a senior author of the study said, “We therefore propose that both of these measurements be carried out in combination in order to better understand the inflammation in asthma patients. They thus constitute a better platform for selecting the proper treatment for these patients.” The study was published in the October 2013 issue of the Journal of Allergy and Clinical Immunology.

Related Links:
Uppsala University
Aerocrine AB
Beckman Coulter


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.